No significant difference in cure rates between treatment and placebo groups
Future development plans under review

RGN-259, a treatment for neurotrophic keratitis being developed by HLB Therapeutics, failed to meet its primary endpoint in a U.S. Phase 3 clinical trial. The company plans to review the full clinical data, analyze the detailed results, and then decide whether and how to proceed with development.

HLB Therapeutics' Neurotrophic Keratitis Drug Fails U.S. Phase 3 Trial View original image

According to HLB Therapeutics on November 16, topline results from the U.S. Phase 3 trial of RGN-259 (SEER-2), conducted by its U.S. subsidiary ReGenTree, showed no statistically significant difference between the treatment and placebo groups in the cure rate four weeks after treatment, the primary endpoint. The company received the results from the contract research organization (CRO) on November 13.


Neurotrophic keratitis is a rare eye disease in which nerve damage in the cornea reduces sensation and prevents corneal wounds from healing properly. In severe cases, ulcers or perforations can develop in the cornea, potentially leading to vision loss.


HLB Therapeutics expects to receive the full clinical data from the CRO within the next few weeks. It will then comprehensively analyze detailed results for the primary endpoint, secondary endpoints, and treatment responses by patient subgroup before deciding whether and how to proceed with development.



CEO Ahn Gihong said, "Although we did not achieve statistical significance for the primary endpoint in these topline results, we will carefully analyze the full clinical data to comprehensively assess detailed results related to the treatment's efficacy. Based on the analysis, we will carefully review the future direction and plans for development and promptly and responsibly pursue any necessary follow-up measures."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing